ADXN Addex Therapeutics Ltd
3.130USD-1.57%Mkt Cap: 5.49M $P/E: —1d ago
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enz…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Addex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ... Addex Therapeutics Ltd (ADXN) posted a stable $3.4 million net loss, regained full GABAB PAM rights from Indivior, and raised $2.8 million to fund operations into Q4 2027. | ||
 Addex (ADXN) Q2 2026 Earnings Call Transcript Biotech regains GABAB rights, extends cash runway into Q4 2027. | ||